Vaccine for the prevention of pneumococcal infections (Vaccinum antipneumococcum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Vaccines, serums, phages and toxoids

Included in the formulation
  • Pneumo 23
    solution w / m PC 
    Sanofi Pasteur S.A.     France
  • Pneumovax® 23 (Vaccine pneumococcal, polyvalent)
    solution w / m PC 
    Merck Sharp and Doum B.V.     Netherlands
  • Prevenar® (pneumococcal polysaccharide conjugated adsorbed vaccine)
    suspension w / m 
    Pfizer Inc.     USA
  • PREVENAR® 13 (vaccine pneumococcal polysaccharide conjugated adsorbed, thirteen-valent)
    suspension w / m 
    Pfizer Inc.     USA
  • Synflorix®
    suspension w / m 
    GlaxoSmithKline Trading, ZAO     Russia
    • АТХ:

    J.07   Vaccines

    J.07.A.L   Vaccine for the prevention of pneumococcal infection

    Pharmacodynamics:

    Highly purified polyvalent vaccine. It is a purified polysaccharide Streptococcus pneumoniae 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F. Causes the formation of immunity to these serotypes Streptococcus pneumoniae. Immunity is acquired 10-15 days after a single vaccination and lasts for at least 5 years. After the introduction of this vaccine seroconversion is observed, at least, in 90% of vaccinated persons.

    Pharmacokinetics:

    No data.

    Indications:

    Prevention of infections of pneumococcal etiology, especially of respiratory tract infections, in persons at risk, starting at the age of two.

    ICD-10

    XXI.Z20-Z29.Z23.8   The need for immunization against another single bacterial disease

    Contraindications:

    Strong reaction to the previous administration of the vaccine; anti-pneumococcal vaccination or pneumococcal disease (caused by one of the vaccine-containing serotypes) for a period of up to 5 years before the planned vaccination with this vaccine.

    Carefully:

    In connection with the possibility of developing serious adverse reactions (such as the phenomenon of Arthus) during vaccination, contraindications should be strictly observed, and the benefits of vaccination should be evaluated. At the same time, it is necessary to take into account that the determination of the effectiveness of the anti-pneumococcal vaccination was carried out only in persons at risk.

    Pregnancy and lactation:

    Despite the fact that information about the adverse effects on the fetus when using this vaccine in pregnancy is not available, vaccination of pregnant women from risk groups is not recommended.

    Dosing and Administration:

    The vaccine is administered subcutaneously or intramuscularly. Primary vaccination is carried out with a single dose of this vaccine once. Revaccination is carried out every five years.The interval between revaccinations can be reduced in individuals from high-risk groups or patients who receive immunosuppressants.

    Side effects:

    There may be weakness, slight increase in body temperature, chills, headache (duration - not more than 24 hours); local reactions - redness, mild soreness or tightness at the injection site.

    Overdose:

    No data.

    Interaction:

    Immunosuppressive therapy can reduce or completely suppress the immune response to the administration of this vaccine.

    Special instructions:

    Vaccination is especially indicated for patients with sickle-cell anemia, as well as persons with asplenia who have undergone splenectomy or before splenectomy.

    When revaccination, performed earlier than the prescribed time, severe local reactions may occur.

    Despite the fact that information about the adverse effects on the fetus when using this vaccine in pregnancy is not available, vaccination of pregnant women from risk groups is not recommended.

    Instructions
    Up